MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis
This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood,...
Saved in:
Published in | Journal of clinical pharmacology Vol. 62; no. 4; p. 463 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
01.04.2022
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA-assisted psychotherapy, patients are subjected to 2 or 3 multihour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress. The use of MDMA-assisted psychotherapy treatment reduced patient's Clinician-Administered PTSD Scale (CAPS) scores from baseline more than control psychotherapy (-22.03; 95%CI, -38.53 to -5.52) but with high statistical heterogeneity. MDMA-assisted psychotherapy enhanced the achievement of clinically significant reductions in CAPS scores (relative risk, 3.65; 95%CI, 2.39-5.57) and CAPS score reductions sufficient to no longer meet the definition of PTSD (relative risk, 2.10; 95%CI, 1.37-3.21) with no detected statistical heterogeneity. While therapy was generally safe and well tolerated, bruxism, anxiety, jitteriness, headache, and nausea are commonly reported. While MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks. |
---|---|
AbstractList | This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA-assisted psychotherapy, patients are subjected to 2 or 3 multihour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress. The use of MDMA-assisted psychotherapy treatment reduced patient's Clinician-Administered PTSD Scale (CAPS) scores from baseline more than control psychotherapy (-22.03; 95%CI, -38.53 to -5.52) but with high statistical heterogeneity. MDMA-assisted psychotherapy enhanced the achievement of clinically significant reductions in CAPS scores (relative risk, 3.65; 95%CI, 2.39-5.57) and CAPS score reductions sufficient to no longer meet the definition of PTSD (relative risk, 2.10; 95%CI, 1.37-3.21) with no detected statistical heterogeneity. While therapy was generally safe and well tolerated, bruxism, anxiety, jitteriness, headache, and nausea are commonly reported. While MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks. |
Author | Hernandez, Adrian V Sicignano, Dakota J Smith, Kimberly W White, C Michael |
Author_xml | – sequence: 1 givenname: Kimberly W surname: Smith fullname: Smith, Kimberly W organization: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA – sequence: 2 givenname: Dakota J surname: Sicignano fullname: Sicignano, Dakota J organization: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA – sequence: 3 givenname: Adrian V orcidid: 0000-0002-9999-4003 surname: Hernandez fullname: Hernandez, Adrian V organization: Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola (USIL), Lima, Peru – sequence: 4 givenname: C Michael orcidid: 0000-0002-9367-4893 surname: White fullname: White, C Michael organization: Research Administration, Hartford Hospital, Hartford, Connecticut, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34708874$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j1tLwzAcxYMo7qIPfgHJF-hM0lxa38rmDVYcbuLjSJt_aMd6IcmUfnsL06dz4MDv8Juhy7ZrAaE7ShaUEPZwKPtqQdNUXKApFYJFXBI-QTPvD4RQyQW9RpOYK5Ikik-Ry1d5FmXe1z6AwRs_lFUXKnC6H7DtHN450KGBNuDO4k3nQ3D61OhQl3gbHHiPV7XvnAH3iDO8HUbMef2A7xp-8FcdKpxD0FHW6uMw_tygK6uPHm7_co4-n592y9do_f7ytszWURmLWETUEEULoyEubUJMoQzlyoqYawkiHQVtqi2TMiVMFhS4pBogHpsqVCEYZ3N0f-b2p6IBs-9d3Wg37P_l2S8GIlxn |
CitedBy_id | crossref_primary_10_1089_derm_2023_0292 crossref_primary_10_3917_heg_131_0002 crossref_primary_10_3389_fpsyt_2024_1411234 crossref_primary_10_1007_s00213_024_06685_8 crossref_primary_10_1177_00048674231203898 crossref_primary_10_1177_08901171231210806e crossref_primary_10_1001_jamapsychiatry_2024_3532 crossref_primary_10_7759_cureus_44905 crossref_primary_10_1080_02791072_2024_2401977 crossref_primary_10_1177_00048674241240597 crossref_primary_10_3389_fpsyt_2022_983285 crossref_primary_10_1177_10600280231199666 crossref_primary_10_1016_j_neulet_2022_136710 crossref_primary_10_1080_02791072_2023_2272832 crossref_primary_10_1038_s41386_023_01656_7 crossref_primary_10_1055_a_2283_0238 crossref_primary_10_1038_s41386_024_01865_8 crossref_primary_10_1016_j_neuropharm_2023_109418 crossref_primary_10_3389_fpsyg_2025_1528253 crossref_primary_10_1007_s11920_024_01577_2 crossref_primary_10_1177_08901171231210806 crossref_primary_10_1038_s41598_023_40856_5 crossref_primary_10_3389_fpubh_2023_1274719 crossref_primary_10_1038_s41598_023_41199_x crossref_primary_10_1080_09540261_2024_2357668 crossref_primary_10_1055_a_2453_0910 crossref_primary_10_1080_02791072_2025_2474246 crossref_primary_10_1177_02537176241294146 crossref_primary_10_1021_acsmedchemlett_2c00389 crossref_primary_10_1038_s41591_023_02705_w crossref_primary_10_7759_cureus_57049 crossref_primary_10_1089_jpm_2022_0036 crossref_primary_10_1016_j_nbd_2023_106348 crossref_primary_10_1176_appi_ajp_20230902 crossref_primary_10_1177_02698811241265762 crossref_primary_10_2174_1570159X21666230428091433 crossref_primary_10_1089_lgbt_2024_0103 crossref_primary_10_36303_SAGP_2022_3_2_0123 crossref_primary_10_1080_02791072_2023_2274382 crossref_primary_10_1002_fhu2_70009 crossref_primary_10_3389_fpsyt_2022_991753 crossref_primary_10_1097_COC_0000000000000998 crossref_primary_10_1126_sciadv_adl6554 crossref_primary_10_1007_s11910_024_01353_y crossref_primary_10_1016_j_psychres_2022_115020 crossref_primary_10_1080_20008066_2024_2366049 crossref_primary_10_1002_npr2_12485 crossref_primary_10_1016_j_nurpra_2023_104586 crossref_primary_10_1016_j_scitotenv_2024_176906 crossref_primary_10_1038_s41380_024_02800_5 crossref_primary_10_5664_jcsm_10074 crossref_primary_10_3390_molecules27092977 crossref_primary_10_1055_a_2282_4731 crossref_primary_10_1177_10600280221144055 crossref_primary_10_1080_13576275_2024_2434456 crossref_primary_10_1007_s00278_024_00715_8 crossref_primary_10_1016_j_ajp_2024_104193 crossref_primary_10_1186_s12909_024_06141_3 crossref_primary_10_3390_jcm11123255 crossref_primary_10_1007_s11920_023_01446_4 crossref_primary_10_3389_fpsyg_2022_866018 crossref_primary_10_1002_jppr_1921 crossref_primary_10_1016_j_psc_2024_04_012 crossref_primary_10_1016_j_euroneuro_2023_05_008 crossref_primary_10_1007_s00213_024_06593_x |
ContentType | Journal Article |
Copyright | 2021, The American College of Clinical Pharmacology. |
Copyright_xml | – notice: 2021, The American College of Clinical Pharmacology. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/jcph.1995 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1552-4604 |
ExternalDocumentID | 34708874 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- .55 .GJ 05W 0R~ 123 18M 1CY 1OB 1OC 29K 33P 34G 39C 3O- 3SF 4.4 52U 52V 53G 5RE 8-1 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADMGS ADNMO ADOZA ADSTG ADXAS AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AI. AIACR AIAGR AIDQK AIDYY AITYG AIURR ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUVAJ AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BOGZA BRXPI C45 CAG CGR COF CS3 CUY CVF D-I DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS ECM EIF EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H13 HF~ HGLYW HVGLF IAO IEA IHR INH INR IVC KBYEO LATKE LEEKS LH4 LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NPM O66 O9- OVD P2P P2W PALCI PQQKQ R.K RIWAO RJQFR ROL SAMSI SUPJJ SV3 TEORI VH1 WBKPD WH7 WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR X7M ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c3535-1d071bdae3cf80db7d147f534a6e59995f9af2669026b1e461aee3b1e7b7b5242 |
IngestDate | Mon Jul 21 06:06:23 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | drug development clinical pharmacology CPH drug abuse psychiatry (PSY) psychopharmacology (PSP) |
Language | English |
License | 2021, The American College of Clinical Pharmacology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3535-1d071bdae3cf80db7d147f534a6e59995f9af2669026b1e461aee3b1e7b7b5242 |
ORCID | 0000-0002-9367-4893 0000-0002-9999-4003 |
PMID | 34708874 |
ParticipantIDs | pubmed_primary_34708874 |
PublicationCentury | 2000 |
PublicationDate | 2022-04-00 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-00 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of clinical pharmacology |
PublicationTitleAlternate | J Clin Pharmacol |
PublicationYear | 2022 |
SSID | ssj0016451 |
Score | 2.5759816 |
SecondaryResourceType | review_article |
Snippet | This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 463 |
SubjectTerms | Combined Modality Therapy Humans N-Methyl-3,4-methylenedioxyamphetamine - adverse effects N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use Psychotherapy Stress Disorders, Post-Traumatic - drug therapy Stress Disorders, Post-Traumatic - psychology Treatment Outcome |
Title | MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34708874 |
Volume | 62 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6lVEK9IF4tb80B9UKXxvE-Gm4RUEVFQZWaot6qXe8uhEcSpe6h_CP-JbNer9duqaBcrMhrW9F-n8Yz45lvCHlpc238a4tyJgVl1jE6VEJQyYQd9q3pF8Y3OE8-ivExOzjhJ73er1bV0nmpXxc__9hX8j-o4jnE1XfJ3gDZ5qF4An8jvnhEhPH4TxhP3k1GFDfYQ2VqWxYaqkIZ5rSpIq8q3c7KcqXOg0brUegRieKboUH9KMk6R8F9n6ad2FLRqF5yjTfbdFgukxZ2k61v0jcfZn7-yPeLVymzMytmn-eqGgCOFPy2KFX6UjVuJ7lHZuWN0af0GqlH-3Vr_-sMBga_qfDF1laXDygTYQ5xNMti0KIfa9lYFiziFdsftGS_FssvvgWTt6_BTVz-qEiQM-ntKvv76iUZ7ri0RtYwIPETVn1aqP5cJRjPomxVf7Db_IcNcjvedylsqdyX6V1yp0YKRoFE90jPzu-T7cMA1sUOTFMf3tkObMNhC8YHZNVhGnSYBsg0aJgGCwcdpkFgGkSmvYERJJ5B4Bl4nkGHZw_J8f776dsxrad10CLnOaeZQW9VG2Xzwu31jZYmY9LxnClhOYYh3A2VQ3dwiFG_ziwTmbJoKTIrtdQcPcVNcmu-mNtHBLjRDrdU4gUF0zbf067QGAtoM8gNs_Ix2Qp7eboMkiyncZefXLvylGwk7j0j6w5tgH2ODmWpX1Rg_gakcHzh |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MDMA-Assisted+Psychotherapy+for+Treatment+of+Posttraumatic+Stress+Disorder%3A+A+Systematic+Review+With+Meta-Analysis&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Smith%2C+Kimberly+W&rft.au=Sicignano%2C+Dakota+J&rft.au=Hernandez%2C+Adrian+V&rft.au=White%2C+C+Michael&rft.date=2022-04-01&rft.eissn=1552-4604&rft.volume=62&rft.issue=4&rft.spage=463&rft_id=info:doi/10.1002%2Fjcph.1995&rft_id=info%3Apmid%2F34708874&rft_id=info%3Apmid%2F34708874&rft.externalDocID=34708874 |